Photo by tomspentys from unsplash
The risk of developing malignancies including cutaneous T-cell lymphoma with use of Janus kinase inhibitors is of concern. Here, we describe a case of Sézary syndrome in a patient during… Click to show full abstract
The risk of developing malignancies including cutaneous T-cell lymphoma with use of Janus kinase inhibitors is of concern. Here, we describe a case of Sézary syndrome in a patient during treatment with baricitinib for seronegative rheumatoid arthritis.
Keywords:
baricitinib seronegative;
zary syndrome;
syndrome patient;
treatment baricitinib;
patient treatment;
case zary
Journal Title: Clinical and experimental dermatology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical and experimental dermatology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!